Page 244 - Genentech News Today

By devoting resources to new business ideas that have yet to prove themselves, venture capital firms wind up creating a more efficient and prosperous society.

And Other People News Announced This Week

The global demand for drug discovery services market is expected to rise at a 14.5% CAGR to acquire a valuation of US$ 50.9 Bn by the end of forecast period 2022-232. The global drug discovery services market size was valued at US$ 15.5 Bn in 2021 and is projected to reach a valuation of US$ 32 Bn by 2026The global...

Novartis reveals details of HQ raid; sustainable energy patenting tails off; Ford to pay $105m for trade secrets misappropriation; ‘Doctor Zhivago’ copyright claim fails; UK ‘counterfeit street’ to be bulldozed

Health news and commentary from around the Web gathered by <em>MedPage Today</em> staff

High-efficacy therapies for multiple sclerosis have improved disease outcomes for many patients, but physicians are uncertain when to use them.

SYDNEY, Oct. 27, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is please...

Vabysmo achieved its primary endpoint of non-inferiority to aflibercept in RVO in the BALATON and COMINO clinical trials Vabysmo was generally well tolerated, with a safety profile consistent with previous

SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of Swiss drug major Roche Group (RHHBY), announced Thursday positive topline results from Phase III trials that showed Vabysmo improved vision

Kazia Therapeutics (KZIA) gained ~31% pre-market Thursday after the oncology-focused biotech announced that its lead candidate, paxalisib demonstrated anti-tumor activity in...